CELMoDs

Aug 24, 2026

Summary In August 2026, the FDA granted accelerated approval to Bristol Myers Squibb’s ZENBEXUS (iberdomide), the first-in-class CELMoD, in combination with daratumumab and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy. Approval rests on the Phase 3 EXCAL...

Jul 25, 2024

Over the years, REVLIMID has become an integral weapon in the cancer therapeutics armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone.  As the wise say,...